|
Real-time Estimate
Cboe BZX
17:34:04 12/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 89.70 USD | +0.20% |
|
+10.13% | +12.87% |
| 12:18pm | Wells Fargo Adjusts Price Target on CVS Health to $112 From $123 | MT |
| 11-11 | CVS Health Corporation Presents at 8th Annual Wolfe Research Healthcare Conference, Nov-09-2026 08:45 AM |
| Market Cap | 115B 104B 95.61B 86.54B 163B 10,768B 168B 1,148B 456B 5,756B 430B 421B 18,323B | P/E 2026 * |
12.7x | P/E 2027 * | 12.3x |
|---|---|---|---|---|---|
| Enterprise Value | 168B 152B 140B 127B 239B 15,786B 247B 1,682B 669B 8,439B 630B 617B 26,862B | EV / Sales 2026 * |
0.4x | EV / Sales 2027 * | 0.38x |
| Free-Float |
71.21% | Yield 2026 * |
2.99% | Yield 2027 * | 3.05% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| CVS | Delayed | |
CBOE
| CVS | Real-time | |
|
Tradegate
| CVS | Real-time | |
|
London S.E.
| 0HRS | Delayed | |
|
Xetra
| CVS | Delayed | |
|
Deutsche Boerse AG
| CVS | Delayed | |
|
Boerse Muenchen
| CVS | Real-time | |
|
Mexican S.E.
| CVS * | End-of-day quote | |
|
Börse Stuttgart
| CVS | Delayed | |
|
Wiener Boerse
| CVS | End-of-day quote | |
|
Santiago S.E.
| CVS | End-of-day quote | |
|
Lima
| CVSUS | End-of-day quote | |
|
Borsa Italiana
| 1CVS | End-of-day quote | |
|
Santiago S.E.
| CVSCL | End-of-day quote | |
|
CBOE
| 0HRS | Real-time | |
|
CBOE
| Real-time | ||
|
Swiss Exchange
| CVS | Delayed | |
|
Swiss Exchange
| CVS | Delayed |
Last Transcript: CVS Health Corporation
| 1 day | +0.18% | ||
| 1 week | +10.13% | ||
| Current month | -0.75% | ||
| 1 month | +2.09% | ||
| 3 months | -5.44% | ||
| 6 months | -5.86% | ||
| Current year | +12.87% |
| 1 week | 80.69 |  | 90.33 |
| 1 month | 77.33 | | 95.26 |
| Current year | 69.51 | | 110.68 |
| 1 year | 69.51 | | 110.68 |
| 3 years | 43.56 | | 110.68 |
| 5 years | 43.56 | | 111.25 |
| 10 years | 43.56 | | 111.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
J. Joyner
CEO | Chief Executive Officer | 62 | 16/10/2024 |
Ali Keshavarz
PSD | President | - | - |
Brian Newman
DFI | Director of Finance/CFO | 57 | 11/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
C. Brown
BRD | Director/Board Member | 74 | 28/02/2007 |
Anne Finucane
BRD | Director/Board Member | 73 | 19/01/2011 |
| Director/Board Member | 71 | 04/03/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 06/11/26 | Buy | Executive/Senior Manager | 23,855 | 0.0019% | ||
| 31/05/26 | Tax | Chief Financial Officer | -2,478 | 0.0002% | ||
| 31/05/26 | Tax | Chief Technology Officer | -7,618 | 0.0006% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.20% | +10.13% | +11.60% | +32.11% | 115B | |
| +0.39% | +0.09% | +7.24% | +120.84% | 106B | |
| +1.16% | -11.64% | +53.42% | +562.14% | 46.38B | |
| +0.81% | +2.80% | +8.04% | +110.94% | 33.01B | |
| +0.38% | +2.84% | +40.46% | +82.78% | 30.23B | |
| +0.88% | +2.56% | +39.82% | +97.40% | 28.46B | |
| -0.68% | +1.60% | +45.52% | +430.40% | 23.32B | |
| +0.33% | +0.09% | -18.10% | -16.30% | 19.85B | |
| +1.42% | +0.77% | -5.54% | +33.11% | 16.77B | |
| +0.66% | +10.77% | +116.85% | - | 15.13B | |
| Average | +0.54% | +0.05% | +29.93% | +161.49% | 43B | |
| Weighted average by Cap. | +0.46% | +1.41% | +22.08% | +147.58% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 422B 381B 352B 319B 601B 39,642B 619B 4,225B 1,679B 21,193B 1,583B 1,549B 67,457B | 431B 389B 359B 325B 614B 40,472B 632B 4,313B 1,714B 21,637B 1,616B 1,581B 68,869B |
| Net income | 9.05B 8.19B 7.56B 6.84B 12.91B 851B 13.29B 90.7B 36.04B 455B 33.97B 33.25B 1,448B | 9.38B 8.48B 7.83B 7.09B 13.37B 882B 13.78B 93.99B 37.35B 471B 35.21B 34.46B 1,501B |
| Net Debt | 53.38B 48.27B 44.56B 40.33B 76.11B 5,018B 78.39B 535B 213B 2,683B 200B 196B 8,539B | 48.65B 43.99B 40.61B 36.76B 69.36B 4,574B 71.44B 487B 194B 2,445B 183B 179B 7,783B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/11/26 | US$89.51 | -0.01% | 2,791,567 |
| 11/11/26 | US$89.52 | +0.57% | 11,082,230 |
| 10/11/26 | US$89.01 | +4.41% | 15,116,051 |
| 09/11/26 | US$85.25 | +1.67% | 11,253,761 |
| 06/11/26 | US$83.85 | +3.10% | 16,099,672 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CVS Stock
Select your edition
All financial news and data tailored to specific country editions
